Orion Corporation, Orion Pharma

🇫🇮Finland

Country: 🇫🇮Finland

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-103 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ODM103
Drug: Placebo
Drug: Entacapone
Drug: Levodopa/carbidopa

First Posted Date: 2012-09-19

Last Posted Date: 2014-09-19

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 67

Registration Number: NCT01688089

Locations: 🇩🇪
Parexel International GmbH, Berlin, Germany

Pharmacokinetic Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Symbicort Turbohaler
Drug: Budesonide/formoterol Easyhaler

First Posted Date: 2012-08-17

Last Posted Date: 2012-11-27

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 48

Registration Number: NCT01668121

Locations: 🇩🇪
PAREXEL International GmbH, Berlin, Germany

Pharmacokinetic Study Comparing Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler Forte

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Budesonide/formoterol Easyhaler
Drug: Symbicort Turbuhaler
Drug: Charcoal and Budesonide/formoterol Easyhaler
Drug: Charcoal and Symbicort Turbuhaler

First Posted Date: 2012-06-25

Last Posted Date: 2012-10-15

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 72

Registration Number: NCT01627158

Locations: 🇩🇪
PAREXEL International GmbH, Berlin, Germany

Comparison of Absorption of Budesonide and Formoterol From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Symbicort Turbuhaler forte
Drug: Charcoal and Symbicort Turbuhaler
Drug: Charcoal and Budesonide/formoterol Easyhaler 320/9 microg
Drug: Budesonide/formoterol Easyhaler 320/9 microg

First Posted Date: 2012-05-08

Last Posted Date: 2012-11-22

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 72

Registration Number: NCT01593826

Locations: 🇫🇮
Orion Pharma Clinical Pharmacology Unit, Espoo, Finland

Prospective Multicentre Non-interventional Study of VANTAS® for the Treatment of Patients With Advanced Prostate Cancer

Completed

Conditions: Prostate Cancer

First Posted Date: 2012-04-10

Last Posted Date: 2014-10-16

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 142

Registration Number: NCT01574846

Locations: 🇸🇪
Urology Dep. Skane Univeristy Hospital, Malmoe, Sweden

Phase I Pharmacokinetic Study (SALBLOCK)

Phase 1

Completed

Conditions: Healthy Volunteer Study

Interventions: Drug: salmeterol / fluticasone propionate

First Posted Date: 2012-03-27

Last Posted Date: 2012-06-26

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 20

Registration Number: NCT01564199

Locations: 🇫🇮
CRST (Clinical Research Services Turku), Turku, Finland

Efficacy and Safety of Ibuprofen in Patients With Ankle Injuries

Phase 3

Completed

Conditions: Pain

Interventions: Drug: Placebo
Drug: Ibuprofen

First Posted Date: 2012-03-26

Last Posted Date: 2013-05-08

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 62

Registration Number: NCT01562717

Locations: 🇫🇮
Terveystalo Lahti, Lahti, Finland

Efficacy and Safety of Ibuprofen in Patients With Ankle Injuries

Phase 3

Completed

Conditions: Pain

Interventions: Drug: Ibuprofen
Drug: Placebo

First Posted Date: 2012-03-26

Last Posted Date: 2013-05-08

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 62

Registration Number: NCT01563289

Locations: 🇫🇮
Terveystalo Lahti, Lahti, Finland

Pharmacokinetic Pilot Study on Budesonide/Formoterol

Not Applicable

Completed

Conditions: Healthy

Interventions: Drug: Budesonide
Drug: Formoterol
Device: Easyhaler
Device: Turbohaler Forte

First Posted Date: 2011-10-24

Last Posted Date: 2012-02-03

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 17

Registration Number: NCT01457716

Locations: 🇩🇪
Parexel International GmbH, Berlin, Germany

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: ODM-201

First Posted Date: 2011-09-05

Last Posted Date: 2017-02-20

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 76

Registration Number: NCT01429064

Locations: 🇫🇮
Turku University Hospital, Turku, Finland
🇺🇸
The Urology Center of Colorado, Wheat Ridge, Colorado, United States
🇪🇪
East-Tallinn Central Hospital, Tallinn, Estonia

and more 14 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy